

Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study

Elisa Alonso-Perez¹, Marian Suarez-Gestal¹, Manuel Calaza¹, Josep Ordi-Ros², Eva Balada², Marc Bijl³, Chryssa Papasteriades⁴, Patricia Carreira⁵, Fotini N. Skopouli⁶, Torsten Witte⁷, Emöke Endreffy⁸, Maurizio Marchini⁹, Sergio Migliaresi¹⁰, Gian Domenico Sebastiani¹¹, Maria Jose Santos¹², Ana Suarez¹³, Francisco J. Blanco¹⁴, Nadia Barizzone¹⁵, Rudolf Pullmann¹⁶, Sarka Ruzickova¹⁷, Bernard R. Lauwerys¹⁸, Juan J. Gomez-Reino^{1,19}, Antonio Gonzalez^{1*}, the European Consortium of SLE DNA Collections[†]

1 Laboratorio de Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria - Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, **2** Internal Medicine, Research Laboratory in Autoimmune Diseases, Hospital Vall d'Hebron, Barcelona, Spain, **3** Department of Internal Medicine and Rheumatology, Martini Hospital, Groningen, The Netherlands, **4** Department of Histocompatibility and Immunology, Evangelismos Hospital, Athens, Greece, **5** Rheumatology Department, Hospital 12 de Octubre, Madrid, Spain, **6** Pathophysiology Department, Athens University Medical School, Athens, Greece, **7** Division of Clinical Immunology, Department of Internal Medicine of the Hannover Medical School, Hannover, Germany, **8** Paediatrics Department, Albert Szent-Györgyi Medical Centre, University of Szeged, Szeged, Hungary, **9** Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Milan, Italy, **10** Rheumatology Unit, Second University of Naples, Naples, Italy, **11** UOC Reumatologia, Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy, **12** Rheumatology Department, Hospital Garcia de Orta and Rheumatology Research Unit, Instituto Medicina Molecular, Lisboa, Portugal, **13** Department of Functional Biology, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain, **14** INIBIC-CH Universitario A Coruña, A Coruña, Spain, **15** Department of Medical Sciences and IRCAD, Eastern Piedmont University, Novara, Italy, **16** Institute of Clinical Biochemistry, Martin Faculty Hospital, Jessenius Medical Faculty, Martin, Slovakia, **17** Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic, **18** Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium, **19** Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain

Abstract

Introduction: Systemic Lupus Erythematosus (SLE) shows a spectrum of clinical manifestations that complicate its diagnosis, treatment and research. This variability is likely related with environmental exposures and genetic factors among which known SLE susceptibility loci are prime candidates. The first published analyses seem to indicate that this is the case for some of them, but results are still inconclusive and we aimed to further explore this question.

Methods: European SLE patients, 1444, recruited at 17 centres from 10 countries were analyzed. Genotypes for 26 SLE associated SNPs were compared between patients with and without each of 11 clinical features: ten of the American College of Rheumatology (ACR) classification criteria (except ANAs) and age of disease onset. These analyses were adjusted for centre of recruitment, top ancestry informative markers, gender and time of follow-up. Overlap of samples with previous studies was excluded for assessing replication.

Results: There were three new associations: the SNPs in *XKR6* and in *FAM167A-BLK* were associated with lupus nephritis (OR = 0.76 and 1.30, P_{corr} = 0.007 and 0.03, respectively) and the SNP of *MCEP2*, which is in chromosome X, with earlier age of disease onset in men. The previously reported association of *STAT4* with early age of disease onset was replicated. Some other results were suggestive of the presence of additional associations. Together, the association signals provided support to some previous findings and to the characterization of lupus nephritis, autoantibodies and age of disease onset as the clinical features more associated with SLE loci.

Conclusion: Some of the SLE loci shape the disease phenotype in addition to increase susceptibility to SLE. This influence is more prominent for some clinical features than for others. However, results are only partially consistent between studies and subphenotype specific GWAS are needed to unravel their genetic component.

Citation: Alonso-Perez E, Suarez-Gestal M, Calaza M, Ordi-Ros J, Balada E, et al. (2012) Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study. PLoS ONE 7(9): e45356. doi:10.1371/journal.pone.0045356

Editor: Yong-Gang Yao, Kunming Institute of Zoology, Chinese Academy of Sciences, China

Received: July 3, 2012; **Accepted:** August 14, 2012; **Published:** September 26, 2012

Copyright: © 2012 Alonso-Perez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: EA-P is the recipient of a pre-doctoral bursary of the Instituto de Salud Carlos III (Spain). This work was supported by grants 08/0744 and 11/01048 and by RETICS Program, RD08/0075 (RIER) of the Instituto de Salud Carlos III (Spain) that are partially financed by the European Regional Development Fund of the European Union, and by grants from the Xunta de Galicia and by DFG KFO 250, TP 03 to TW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Antonio.Gonzalez.Martinez-Pedrayo@sergas.es

† Other contributors to the European Consortium of SLE DNA Collections are provided in the Acknowledgments.

Introduction

Systemic Lupus Erythematosus shows a wide spectrum of clinical manifestations and laboratory findings that complicate its diagnosis, treatment and research [1,2]. We do not know the causes of this variability, but likely contributing elements are environmental exposures and genetic factors. Understanding the relationships between these factors and the SLE clinical features will help elucidate disease mechanisms and could provide the basis for a classification of patients in more homogeneous subgroups.

Many associations between genetic polymorphisms and the presence of specific SLE clinical features have been reported, but they have not yet reached a high degree of confidence [3,4,5]. This situation is similar to what had happened in relation to SLE susceptibility until 2008 when the first SLE GWAS were published. Now, there are about 30 loci that are consistently associated with SLE susceptibility [6,7,8]. These loci are prime candidates for having a predisposing effect for specific SLE clinical features. The first analyses seem to indicate that this is the case for some of them [9,10,11,12,13,14,15], but results are still inconclusive. For example, the *rs7574865* SNP in *STAT4* has been associated with a severe SLE phenotype defined by nephritis, age at diagnosis <30 years old, immunologic disorder (and, specifically, double-stranded DNA autoantibodies) and absence of oral ulcers [10]. The association with immunologic disorder (and anti-dsDNA) and an increase in nephritis prevalence were also reported in two other studies, but not the associations with early onset or lack of oral ulcers [9,13]. In contrast, a fourth study has reported protection from oral ulcers but not association with any of the other subphenotypes [14].

Herein, we have analyzed the association with SLE clinical features of 26 SNPs that tag SLE susceptibility loci in 1444 European patients. Significant associations of renal involvement with *XKR6* and *FAM167A-BLK* SNPs and of earlier age of disease onset and the *MECP2* SNP in men were found. In addition, other weak signals of association were detected that together with concordant previous results obtained in non-overlapping samples suggest a wider involvement of the susceptibility loci in shaping some aspects of the SLE phenotype.

Materials and Methods

Ethic Statement

This study was conducted according to the principles expressed in the Declaration of Helsinki. All subjects provided their written informed consent as approved by the respective ethical committees and the overall study was approved by the Comité Ético de Investigación Clínica de Galicia.

Clinical and Genotype Data

Patients used in this study have already been described [16,17]. Briefly, 17 recruiting centres from 10 European countries were asked for about 100 SLE patients according with ACR criteria [18], all of them with uniform ancestry from the country of recruitment. Clinical characteristics of the patients were obtained at the same time. They included the ACR classification criteria, gender, age of disease onset, and time of follow-up. Genotypes of 26 SNPs tagging SLE loci identified in large studies [19,20,21,22,23,24,25,26,27,28] were available to us from previous studies [16,29,30]. They include 2 SNPs tagging the risk and the protective haplotypes of *IRF5* [29], 10 tag SNPs for 10 SLE loci [16], and the 14 tag SNPs in 12 SLE loci [30]. In addition, genotypes of six (*rs6730157*, *rs382259*, *rs4988235*, *rs12203592*, *rs354690* and *rs12913832*) top ancestry informative markers

Table 1. Clinical characteristics of the patients with SLE included in the analyses.

Features	value	% available information
Women (%)	90.5	99.4
Age at disease onset (mean, SD)	30.7 (13.0)	95.8
Time of follow-up (mean, SD)	12.0 (8.4)	83.5
Malar rash (%)	56.0	93.8
Discoid rash (%)	17.7	99.5
Photosensitivity (%)	52.2	99.9
Oral ulcers (%)	27.4	99.9
Arthritis (%)	79.0	100.0
Serositis (%)	35.3	99.9
Renal disorder (%)	41.6	100.0
Neurologic disorder (%)	14.6	94.0
Hematologic disorder (%)	72.9	97.1
Immunologic disorder (%)	77.9	99.5

doi:10.1371/journal.pone.0045356.t001

(AIM) have also been obtained previously [17]. The three first are the most informative AIMs in differentiating Northern from Southern European subpopulations, and *rs12203592* and *rs354690* are the two AIMs more informative for East-West differentiation, identified in a study analyzing 300 000 SNPs in 4000 European subjects [31]. Results from *rs4988235* were not used for analysis because it was largely redundant with *rs6730157* in our samples ($r^2 = 0.87$). *rs12913832* is a SNP associated with large differences in frequency across Europe and unrelated with the previous [32].

Association Analysis

We compared SNP genotype frequencies between cases positive and negative for each of the ACR classification criteria (except presence of ANA given that they were almost uniformly positive) and age of disease onset. Only patients with information of at least 9 of these 11 features were included in the study (Table 1). The comparisons were done with logistic regression following a genetic additive model with codes 2 for aa genotypes, 1 for aA genotypes and 0 for the AA genotypes. Possible confounding factors were included as covariates in the regression model. These included the 17 recruiting centres as dichotomous variables with value 1 if the sample came from that centre and 0 otherwise. We added also as covariates the patient genotypes at the five top AIMs. In addition, a variable with codes 1 for samples from the Iberian Peninsula and 0 from the rest of samples was added for the analysis of oral ulcers because this is an important differential factor for this clinical feature [30]. Results with $P < 0.05$ at this stage were further analyzed by stratifying by patient gender and by including as covariate time of follow-up. Bonferroni correction for multiple tests was applied considering the number of analyzed clinical features. To compare our results with previous reports, samples from collections that have participated in any of them were excluded. These analyses were done in a customized version of Statistica 7.0 (StatSoft, Tulsa, OK, USA).

Results

We collected DNA samples and clinical information from 1742 patients with SLE from 17 recruiting centres in 10 European

Table 2. SNPs tagging SLE susceptibility loci with indication of their association in the study where they were discovered and in our current samples [16,29,30].

SNP	Locus	SNP discovery study		Ref.	Current study	
		OR (95% CI)	P		OR (95% CI)	P
rs2187668	<i>HLA-DQA1</i>	1.9 (1.7–2.2)	3.0×10^{-21}	22	2.2 (1.9–2.5)	1.1×10^{-25}
rs10488631	<i>IRF5</i>	1.7 (1.5–1.9)	1.7×10^{-11}	22	2.0 (1.7–2.3)	8.4×10^{-21}
rs3131379	<i>MSH5</i>	2.4 (2.1–2.6)	1.7×10^{-52}	21	2.3 (1.9–2.7)	6.4×10^{-20}
rs1143679	<i>ITGAM</i>	1.8 (1.6–2.0)	1.7×10^{-17}	25	1.7 (1.5–1.9)	1.1×10^{-16}
rs7574865	<i>STAT4</i>	1.5 (1.2–1.8)	2.8×10^{-9}	21	1.6 (1.4–1.9)	2.4×10^{-12}
rs2230926	<i>TNFAIP3</i>	2.0 (1.4–3.0)	3.0×10^{-4}	24	2.0 (1.6–2.5)	2.5×10^{-10}
rs729302	<i>IRF5</i>	0.7 (0.5–0.8)	6.7×10^{-3}	19	0.7 (0.7–0.8)	1.7×10^{-7}
rs13277113	<i>FAM167A-BLK</i>	1.4 (1.3–1.5)	1.1×10^{-10}	22	1.3 (1.2–1.5)	5.1×10^{-7}
rs2304256	<i>TYK2</i>	0.6 (0.5–0.8)	5.6×10^{-5}	19	0.8 (0.7–0.9)	2.5×10^{-5}
rs5754217	<i>UBE2L3</i>	1.2 (1.1–1.3)	7.5×10^{-8}	21	1.3 (1.1–1.4)	7.3×10^{-5}
rs10798269	<i>1q25.1</i>	0.8 (0.8–0.9)	1.1×10^{-7}	21	0.8 (0.7–0.9)	1.3×10^{-4}
rs2205960	<i>TNFSF4</i>	1.3 (1.1–1.5)	7.0×10^{-3}	20	1.3 (1.1–1.4)	1.3×10^{-4}
rs844644	<i>TNFSF4</i>	0.7 (0.6–0.8)	6.8×10^{-5}	20	0.8 (0.7–0.9)	7.2×10^{-4}
rs17435 ^a	<i>MECP2</i>	1.3 (1.1–1.5)	8.0×10^{-4}	26	1.3 (1.1–1.4)	8.5×10^{-4}
rs2476601	<i>PTPN22</i>	1.5 (1.3–1.8)	5.2×10^{-6}	21	1.3 (1.1–1.6)	9.2×10^{-4}
rs4963128	<i>KIAA1542</i>	0.8 (0.7–0.9)	3.0×10^{-10}	21	0.8 (0.8–0.9)	1.1×10^{-3}
rs1801274	<i>FCGR1IA</i>	1.4 (1.2–1.5)	6.8×10^{-7}	21	1.2 (1.1–1.3)	1.3×10^{-3}
rs6920220	<i>TNFAIP3</i>	1.2 (1.1–1.3)	4.0×10^{-7}	27	1.2 (1.1–1.4)	2.3×10^{-3}
rs6445975	<i>PXK</i>	1.3 (1.2–1.4)	7.1×10^{-10}	21	1.2 (1.1–1.3)	3.8×10^{-3}
rs573775	<i>ATG5</i>	1.2 (1.1–1.3)	1.4×10^{-7}	21	1.2 (1.1–1.3)	4.4×10^{-3}
rs17266594	<i>BANK1</i>	0.7 (0.6–0.8)	4.7×10^{-11}	23	0.8 (0.7–0.9)	6.2×10^{-3}
rs4240671	<i>XKR6</i>	0.75 (0.7–0.8)	6.6×10^{-9}	21	0.9 (0.8–1.0)	0.11
rs10156091	<i>ICA1</i>	1.3 (1.2–1.5)	1.9×10^{-7}	21	1.1 (0.9–1.3)	0.3
rs2667978	<i>LYN</i>	0.8 (0.7–0.8)	5.1×10^{-8}	21	0.9 (0.8–1.1)	0.3
rs509749	<i>LY9</i>	377:403 ^b	2.1×10^{-3}	28	1.0 (0.9–1.1)	0.5
rs6922466	<i>PERP</i>	0.8 (0.7–0.9)	1.0×10^{-4}	24	1.0 (0.9–1.1)	0.8

OR: Odds ratio. CI: confidence interval.

^aOnly women. The result for men in our samples was O.R. = 2.11 (1.3–3.4), $P = 0.001$.

^bObserved:Expected in transmission disequilibrium test.

doi:10.1371/journal.pone.0045356.t002

countries. They were ascertained to have a uniform self-reported origin from the country of recruitment and genotyped for top AIMs informative about European population substructure. We required for inclusion in this study that each patient should have complete genotypes for the top AIMs and almost complete clinical information defined as 9 or more of the following data: ACR classification criteria, gender and age of disease onset. These conditions were fulfilled for 1444 patients (Table 1). We had already genotyped these samples for 26 SNPs tagging independent SLE association signals [16,29,30], which have been identified in other large studies (Table 2). All of them have passed our quality control filters and most of them were significantly associated in our samples and showed the same direction of change and a very similar effect size than the reported in the study where they were discovered (Table 2; and Table S1 for individual genotypes). There were only 5 of these SNPs that were non-associated in our samples.

In the current case-only analysis, we compared genotype frequencies of each of the SLE SNPs between SLE patients showing the clinical features with those not showing them. All the analyses were adjusted for recruiting centre and for the five top

non-redundant AIMs. This is necessary because some of the features and some of the SLE risk alleles are known to vary between European subpopulations [17,30,33,34,35].

Renal disorder was the clinical feature showing more association signals (Table 3). It was associated with the *XKR6*, *FAM167A-BLK*, *TNFSF4* and *ICA1* SNPs. Only the effect of *FAM167A-BLK* was of increased risk with the SLE risk allele. In all the others the risk allele was protective for nephritis. All these associations persisted after adjusting for gender and time of follow-up (Table S2) and the two first, with *XKR6* and *FAM167A-BLK* SNPs, were significant after correction by the number of tests (Table 3).

Age of disease onset, either as a dichotomous or as a continuous variable, was also nominally associated with three SLE loci (Table 3). There was association with age at onset with the *ATG5*, *STAT4* and *MECP2* SNPs. The association with *MECP2* was the unique association over the threshold for multiple tests. However, special caution with this result is required because it was observed only in men. They were analyzed separately from women because this locus is in the X chromosome. The risk allele of *ATG5* was associated with older age of onset and the risk alleles of the other two loci with younger onset. These association signals did not

Table 3. SLE clinical characteristics showing association with SLE susceptibility SNPs.

Feature	SNP	Locus	P	OR (95% CI)	<i>P_{corr}</i>
Renal disorder	rs4240671	<i>XKR6</i>	0.0006	0.76 (0.7–0.9)	0.007
	rs13277113	<i>FAM167A-BLK</i>	0.003	1.30 (1.1–1.5)	0.03
	rs10156091	<i>ICA1</i>	0.03	0.76 (0.6–1.0)	0.3
	rs844644	<i>TNFSF4</i>	0.04	0.85 (0.7–1.0)	0.4
Disease onset <30	rs573775	<i>ATG5</i>	0.005	0.78 (0.7–0.9)	0.06
	rs7574865	<i>STAT4</i>	0.03	1.20 (1.0–1.4)	0.3
	rs17435	<i>MECP2</i> ^a	0.003	1.92 (1.2–3.0)	0.03
Disease onset full range	rs7574865	<i>STAT4</i>	0.02	–1.21 (–2.2 –0.2) ^b	0.2
	rs17435	<i>MECP2</i> ^a	0.02	–3.57 (–6.6 –0.5) ^b	0.3
Immunologic disorder	rs2205960	<i>TNFSF4</i>	0.01	1.39 (1.1–1.8)	0.1
	rs509749	<i>LY9</i>	0.01	1.31 (1.1–1.6)	0.2
	rs4240671	<i>XKR6</i>	0.04	0.81 (0.7–1.0)	0.5
Neurologic disorder	rs10488631	<i>IRF5</i>	0.01	0.64 (0.5–0.9)	0.1
	rs509749	<i>LY9</i>	0.04	1.26 (1.0–1.6)	0.4
Serositis	rs2667978	<i>LYN</i>	0.02	0.79 (0.7–1.0)	0.2
	rs2304256	<i>TYK2</i>	0.03	1.23 (1.0–1.5)	0.3
Discoid rash	rs729302	<i>IRF5</i>	0.02	0.75 (0.6–1.0)	0.2
	rs2304256	<i>TYK2</i>	0.03	1.29 (1.0–1.6)	0.3
Photosensitivity	rs1801274	<i>FCGR1IA</i>	0.03	1.19 (1.0–1.4)	0.3
	rs2205960	<i>TNFSF4</i>	0.03	1.22 (1.0–1.5)	0.3
Hematologic disorder	rs3131379	<i>MSH5</i>	0.03	1.37 (1.0–1.8)	0.3
Oral ulcers	rs2476601	<i>PTPN22</i>	0.04	0.72 (0.5–1.0)	0.5

^aMen only.^bCoefficient of the linear regression.

doi:10.1371/journal.pone.0045356.t003

improve by considering age of onset in its full quantitative range with linear regression (Table 3 and rs573775 in *ATG5*, $P=0.3$). The association of *STAT4* with earlier SLE onset had already been reported and with a very similar odds ratio (OR) in a study that did not include overlapping samples with the current one [10].

None of the remaining association signals obtained with other clinical features was over the threshold accounting for multiple tests (Table 3). Among the weak association signals there were three with immunological disorder: *TNFSF4*, *LY9* and *XKR6*. Neurologic disorder was nominally associated with SNPs in *IRF5* and *LY9*, serositis with SNPs in *LYN* and *TYK2*, discoid rash with SNPs in *IRF5* and *TYK2*, photosensitivity with SNPs in *FCGR2A* and *TNFSF4*, hematologic disorder with the SNP in *MSH5*, and oral ulcers with the *PTPN22* nsSNP. None of these nominal associations has previously been reported. In addition, we did not replicate any of the other previously reported associations beyond the already commented of *STAT4* with early disease onset (Table 4). However, some of our results were concordant in direction and magnitude as between the *TNFSF4* SNP and lupus nephritis [14], and *STAT4* SNP and protection from oral ulcers or risk to immunologic disorder [10,14].

Discussion

Our study has found that some of the SLE susceptibility loci contribute to shape the SLE phenotype. In addition, it has shown more associations with some clinical features than with others, with a pattern that is reproducible and that indicates the most productive SLE subphenotypes for future projects. Some of the specific associations start to be consistently observed in different studies, although our results are not strong enough to firmly establish them. Three of the associations we have found were over the threshold accounting for multiple tests and one replicated a previous finding. Some of the remaining associations were also of interest because they were concordant in direction and magnitude with previous reports.

The clearest associations were found between renal disorder and SNPs in the *XKR6* and *FAM167A-BLK* loci. Both associations remained significant after correction for multiple tests. *XKR6* was found associated with SLE in the SLEGEN GWAS with 5 SNPs showing $P < 5 \times 10^{-8}$, although it was not highlighted because they were not uniformly associated in the 4 sets of samples included in that study [21]. There has been independent replication of one of the SNPs in a subsequent study [36]. The SNP reported here was not associated with SLE in our samples (Table 2), and none of the *XKR6* SNPs were associated in the largest attempt to replicate SLE GWAs results [27]. Therefore the status of this locus in SLE susceptibility is still uncertain. We are not aware of any previous attempt to explore association between SNPs in this gene and SLE clinical features. The *XKR6* gene codes for one of the transmembrane proteins of the Kell blood group of antigens expressed in red blood cells, although it is also expressed in other tissues. Its possible role in SLE is completely unclear because almost nothing is known about this protein.

Association between lupus nephritis and the SLE risk allele of rs13277113 in the *FAM167A-BLK* locus remained significant after correcting for the number of tests, and was consistently observed in women and men. The same SNP has already been analyzed for association with SLE classification criteria in two previous overlapping studies [14,22], but no association with renal involvement was found. A third overlapping study analyzed a different SNP with the same result [13]. As these previous studies are very large, the association we have found should be considered only as tentative.

The third significant association in our study was found between earlier age at disease onset and the risk allele of the *MECP2* SNP. This association should be taken with special caution because it was restricted to men and there were only 137 men with SLE among our patients.

Other signals of association were found, but none was significant after correction for multiple tests. Overall the associations seem to concentrate in some clinical features: renal disorder, age at onset and immunological disorder are the clearest. In contrast, there are clinical phenotypes that did not appear in any analysis, like malar rash or arthritis. This is in agreement with previous reports where also renal disorder, different types of autoantibodies and age of disease onset are prominent [9,10,11,12,13,14].

Replication of the association of individual locus with specific SLE phenotypes was only obtained for the previous association between *STAT4* and early age of disease onset [10]. Our study was completely independent from the original study and, therefore, it constitutes formal replication. In addition, our results showed some trends that followed the same direction observed in previous reports. The clearest examples are the associations of a *TNFSF4* SNP with lupus nephritis [14], and the protection conferred by

Table 4. Comparison of previous significant SLE subphenotype associations in case-only analysis with our results regarding the same SNPs.

Feature	SNP	Locus	Previous studies		Ref.	Current study	
			OR (95% CI)	P		OR (95% CI)	P
Renal disorder	rs2205960	TNFSF4	1.18 (1.1–1.3)	0.003	14	1.16 (0.9–1.5) ^a	0.2 ^a
	rs1143679	ITGAM	1.39 (1.2–1.7)	0.0003	11	1.13 (0.9–1.4)	0.2
	rs7574865	STAT4	1.23(1.0–1.5)	0.02	10	0.91 (0.8–1.1)	0.3
	rs2187668	HLA-DQA1	1.37 (1.1–1.6)	0.0006	13	1.03 (0.9–1.2)	0.8
Disease onset <30	rs7574865	STAT4	1.22 (1.0–1.4)	0.02	10	1.20 (1.0–1.4)	0.03
Immunologic disorder	rs7574865	STAT4	1.24 (1.0–1.5)	0.02	10	1.16 (0.9–1.5)	0.2
	rs1143679	ITGAM	1.30 (1.0–1.7)	0.04	11	1.10 (0.8–1.4)	0.5
	rs4963128	KIAA1542	0.79 (0.7–0.9)	0.002	13	0.98 (0.8–1.2)	0.9
Oral ulcers	rs7574865	STAT4	0.80 (0.7–0.9)	0.009	10	0.84 (0.7–1.0)	0.07
Malar rash	rs1801274	FCGR3A	1.14 (1.0–1.3)	0.01	14	1.10 (0.9–1.3) ^a	0.4 ^a
Hematologic disorder	rs13277113	FAM167A-BLK	1.23 (1.0–1.5)	0.02	22	1.07 (0.9–1.3)	0.5
Discoid rash	rs1143679	ITGAM	1.27 (1.0–1.6)	0.02	11	1.01 (0.8–1.3)	0.9

^aOR (95% CI) and P values calculated excluding patients from The Netherlands, Germany, Belgium, Hungary, Asturias (Spain), Rome (Italy) and Naples (Italy) which overlapped with the used in [14] under the BIOLUPUS collection.
doi:10.1371/journal.pone.0045356.t004

STAT4 for oral ulcers [10,14]. For these two comparisons, our results showed the reported direction of change but they were not significant, specially when the samples overlapping between our study and the Sanchez et al. study [14] were excluded. These coincidences are encouraging and they give further motivation for additional studies.

Unfortunately, lack of replication of association results regarding clinical phenotypes is still very common. For example, in two large studies there were 8 claims of association (5 plus 3, respectively), but none was coincident in spite of overlap between the samples [13,14]. Probably, these results, as well as ours, are reflection of two types of obstacles. The first is related with the studied loci because a weak phenotype specificity of these loci is implied in the fact that they have been identified in studies involving a wide spectrum of patients with SLE. This circumstance makes it likely that many SNPs with association to particular SLE features will be missing from the list of SLE susceptibility loci. This is exemplified by the *FCGR3A* V158F polymorphism that is associated with lupus nephritis, but not with SLE susceptibility overall [37]. Therefore, it is likely that phenotype-specific GWAs will be more informative. As a first step, a reanalysis of the available GWAs stratified by clinical features could provide useful leads. The second type of obstacles is due to the analysis of subphenotypes, which are highly variably between patients, centres and ethnic groups [10,17,22,34,35,38,39,40,41]. To account for these factors, we have restricted our analyses to subjects of European ancestry and we have adjusted our results for centre of recruitment and for AIMs informative of population substructure. These are precautions that have not been used uniformly in the studies of this type. However, it is not possible through analysis to recover the lost statistical power due to variability between the collections and division of the available data in strata. These properties of the analysis of subphenotypes are typical of any subgroup analysis and make replication of results more difficult [42].

In spite of the difficulties and that these are still early times for these studies; there are results that start to be consistent. They include the concordances we have already signalled relating

STAT4 with earlier disease onset or oral ulcers [10,14]. Also, encouraging are the results relative to the association of *ITGAM* with nephritis, which has already been reported in four studies and that showed the same direction in our samples [11,12,14,15]. A clinical characteristic not included in the current study, the production of anti-dsDNA, has also shown reproducible association with some SLE loci [9,10,13].

Conclusion

In summary, we have found some new genetic associations with SLE clinical features among the SLE susceptibility loci. They confirm the hypothesis that some of these loci shape the SLE phenotype in addition to increase susceptibility to the disease. Our results also support a gradation in the clinical features showing association with these loci: with lupus nephritis, immunologic disorder and age of onset showing the most numerous and clear associations. There were three new associations, *XKR6* and *FAM167A-BLK* with lupus nephritis and *MECP2* with early onset of SLE in men, which need to be taken with caution because either they have never been explored before, or they were not found in previous studies. Replication of the association between early age of disease onset and *STAT4* was obtained. Results for other specific associations showed consistency with previous results without amounting to replication. Overall, results in this field show the need to start GWAS specific for SLE subphenotypes either by reanalysis of existing data or through new studies. A prime candidate for these studies is renal disorder because of its clinical relevance and its prominent association with known SLE loci.

Supporting Information

Table S1 Individual genotypes for the 26 SNPs tagging SLE loci in the patients included in the study. Sex, 0 = male; 1 = female; genotypes, 0 = AA, 1 = Aa and 2 = aa. (XLS)

Table S2 SLE clinical characteristics showing association with SLE susceptibility SNPs including data adjusted by gender and time of follow-up. ^aThis result is only for

men and therefore the adjustment has been made only for time of follow-up.

(XLS)

Acknowledgments

Other contributors to the European Consortium of SLE DNA

Collections: Myriam Liz, Laboratorio de Investigacion 10 and Rheumatology Unit, Instituto de Investigacion Sanitaria – Hospital Clinico Universitario de Santiago. Santiago de Compostela, Spain; Reinhold E Schmidt, Division of Clinical Immunology, Department of Internal Medicine of the Hannover Medical School. Hannover, Germany; Iris Kappou-Rigatou, Department of Histocompatibility and Immunology, Evangelismos Hospital. Athens, Greece; Raffaella Scorza, Clinical Immunology, University of Milan and Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena. Milan, Italy; Attila Kovacs, Department of Rheumatology, Hospital of Hungarian Railways. Szolnok, Hungary; Eva Balada, Internal Medicine, Research Laboratory in Autoimmune Diseases Hospital Vall d'Hebron. Barcelona, Spain; Cees G Kallenberg, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen. Groningen, The Netherlands; Filipe Vinagre, Rheumatology Department, Hospital Garcia de Orta,

Almada (Portugal) and Rheumatology Research Unit, Instituto Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa (Portugal); Ctibor Dostal, Molecular Biology and Immunogenetics Dept, Institute of Rheumatology. Prague, Czech Republic; Rudolf Pullmann Jr, Gerontology Research Center, National Institute on Aging. Nathan Shock Drive, Baltimore, Maryland, USA; Maria Mavromati, Pathophysiology Department, Athens University Medical School. Athens, Greece; Sandra D'Alfonso, Dept Medical Sciences and IRCAD, Eastern Piedmont University. Novara, Italy; Carmen Gutierrez, Department of Functional Biology, Hospital Universitario Central de Asturias, Universidad de Oviedo. Oviedo, Spain; Ignacio Rego, Laboratorio de Investigación Osteoarticular y del Envejecimiento, Servicio de Reumatología. CH Universitario A Coruña. A Coruña, Spain.

Author Contributions

Conceived and designed the experiments: EA-P MS-G AG. Performed the experiments: EA-P MS-G AG. Analyzed the data: EA-P MS-G MC JO-R EB MB CP PC FNS TW EE MM SM GDS MJS AS FJB NB RP SR BRL JJG-R AG. Contributed reagents/materials/analysis tools: JO-R EB MB CP PC FNS TW EE MM SM GDS MJS AS FJB NB RP SR BRL JJG-R. Wrote the paper: EA-P MS-G AG.

References

- Wallace DJ, Hahn B, Dubois EL (2007) Dubois' lupus erythematosus. Philadelphia: Lippincott Williams & Wilkin. xvii, 1414 p.
- Eisenberg R (2009) Why can't we find a new treatment for SLE? *J Autoimmun* 32: 223–230.
- Tsao BP (2004) Update on human systemic lupus erythematosus genetics. *Curr Opin Rheumatol* 16: 513–521.
- Lauwerys BR, Wakeland EK (2005) Genetics of lupus nephritis. *Lupus* 14: 2–12.
- Sestak AL, Nath SK, Sawalha AH, Harley JB (2007) Current status of lupus genetics. *Arthritis Res Ther* 9: 210.
- Rhodes B, Vyse TJ (2008) The genetics of SLE: an update in the light of genome-wide association studies. *Rheumatology (Oxford)* 47: 1603–1611.
- Moser KL, Kelly JA, Lessard CJ, Harley JB (2009) Recent insights into the genetic basis of systemic lupus erythematosus. *Genes Immun* 10: 373–379.
- Deng Y, Tsao BP (2010) Genetic susceptibility to systemic lupus erythematosus in the genomic era. *Nat Rev Rheumatol* 6: 683–692.
- Sigurdsson S, Nordmark G, Garnier S, Grundberg E, Kwan T, et al. (2008) A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. *Hum Mol Genet* 17: 2868–2876.
- Taylor KE, Remmers EF, Lee AT, Ortmann WA, Plenge RM, et al. (2008) Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. *PLoS Genet* 4: e1000084.
- Kim-Howard X, Maiti AK, Anaya JM, Bruner GR, Brown E, et al. (2009) ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash, and immunologic manifestations in lupus patients with European ancestry. *Ann Rheum Dis*.
- Yang W, Zhao M, Hirankarn N, Lau CS, Mok CC, et al. (2009) ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. *Hum Mol Genet* 18: 2063–2070.
- Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, et al. (2011) Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. *PLoS Genet* 7: e1001311.
- Sanchez E, Nadig A, Richardson BC, Freedman BI, Kaufman KM, et al. (2011) Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. *Ann Rheum Dis* 70: 1752–1757.
- Warchol T, Lianeri M, Lacki JK, Olesinska M, Jagodzinski PP (2011) ITGAM Arg77His is associated with disease susceptibility, arthritis, and renal symptoms in systemic lupus erythematosus patients from a sample of the Polish population. *DNA Cell Biol* 30: 33–38.
- Suarez-Gestal M, Calaza M, Endreffy E, Pullmann R, Ordi-Ros J, et al. (2009) Replication of recently identified systemic lupus erythematosus genetic associations: a case-control study. *Arthritis Res Ther* 11: R69.
- Alonso-Perez E, Suarez-Gestal M, Calaza M, Witte T, Papasteriades C, et al. (2011) Association of systemic lupus erythematosus clinical features with European population genetic substructure. *PLoS One* 6: e29033.
- Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 40: 1725.
- Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, et al. (2005) Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. *Am J Hum Genet* 76: 528–537.
- Cunningham Graham DS, Graham RR, Manku H, Wong AK, Whittaker JC, et al. (2008) Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. *Nat Genet* 40: 83–89.
- Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al. (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PTK, KIAA1542 and other loci. *Nat Genet* 40: 204–210.
- Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, et al. (2008) Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. *N Engl J Med* 358: 900–909.
- Kozyrev SV, Abelson AK, Wojcik J, Zaghool A, Linga Reddy MV, et al. (2008) Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. *Nat Genet* 40: 211–216.
- Musone SL, Taylor KE, Lu TT, Niutham J, Ferreira RC, et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. *Nat Genet* 40: 1062–1064.
- Nath SK, Han S, Kim-Howard X, Kelly JA, Viswanathan P, et al. (2008) A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. *Nat Genet* 40: 152–154.
- Sawalha AH, Webb R, Han S, Kelly JA, Kaufman KM, et al. (2008) Common variants within MECP2 confer risk of systemic lupus erythematosus. *PLoS One* 3: e1727.
- Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, et al. (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. *Nat Genet* 41: 1228–1233.
- Cunningham Graham DS, Vyse TJ, Fortin PR, Montpetit A, Cai YC, et al. (2008) Association of LY9 in UK and Canadian SLE families. *Genes Immun* 9: 93–102.
- Ferreiro-Neira I, Calaza M, Alonso-Perez E, Marchini M, Scorza R, et al. (2007) Opposed independent effects and epistasis in the complex association of IRF5 to SLE. *Genes Immun* 8: 429–438.
- Alonso-Perez E, Suarez-Gestal M, Calaza M, Sebastiani GD, Pullmann R, et al. (2012) Bias in effect size of systemic lupus erythematosus susceptibility loci across Europe: a case-control study. *Arthritis Res Ther* 14: R94.
- Tian C, Plenge RM, Ransom M, Lee A, Villoslada P, et al. (2008) Analysis and application of European genetic substructure using 300 K SNP information. *PLoS Genet* 4: e4.
- Han J, Kraft P, Nan H, Guo Q, Chen C, et al. (2008) A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. *PLoS Genet* 4: e1000074.
- Gregersen PK, Lee HS, Batliwalla F, Begovich AB (2006) PTPN22: setting thresholds for autoimmunity. *Semin Immunol* 18: 214–223.
- Chung SA, Tian C, Taylor KE, Lee AT, Ortmann WA, et al. (2009) European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. *Arthritis Rheum* 60: 2448–2456.
- Richman IB, Chung SA, Taylor KE, Kosoy R, Tian C, et al. (2010) European population substructure correlates with systemic lupus erythematosus endophenotypes in North Americans of European descent. *Genes Immun* 11: 515–521.
- Budarf ML, Goyette P, Boucher G, Lian J, Graham RR, et al. (2011) A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. *Genes Immun* 12: 51–58.
- Karassa FB, Trikalinos TA, Ioannidis JP (2003) The Fc gamma RIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. *Kidney Int* 63: 1475–1482.

38. Cervera R, Abarca-Costalago M, Abramovicz D, Allegri F, Annunziata P, et al. (2006) Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". *Autoimmun Rev* 5: 180–186.
39. Al Arfaj AS, Khalil N (2009) Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. *Lupus* 18: 465–473.
40. Alarcon GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, et al. (2002) Baseline characteristics of a multiethnic lupus cohort: PROFILE. *Lupus* 11: 95–101.
41. Pons-Estel BA, Catoggio LJ, Cardiel MH, Soriano ER, Gentiletti S, et al. (2004) The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics". *Medicine (Baltimore)* 83: 1–17.
42. Guillemin F (2007) Primer: the fallacy of subgroup analysis. *Nat Clin Pract Rheumatol* 3: 407–413.